What Caught Our Attention: Regular readers will be familiar with the saga involving Fazlul Sarkar and PubPeer: In 2014, Sarkar sued anonymous commenters on the site, claiming defamation (and that damaging comments may have cost him a new job). Although Sarkar won an initial ruling, it was overturned by an appeals court. In the midst of that, the ACLU (which represented PubPeer in the case) released a copy of a misconduct investigation report compiled by Sarkar’s institution, Wayne State University, which concluded that he had committed enough misconduct to warrant retracting 40 papers. The two latest notices, both of which cite Wayne State’s investigation, bring Sarkar’s total to 21. Continue reading Caught Our Notice: Researcher who sued PubPeer commenter up to 21 retractions
What Caught Our Attention: We’ve been following cancer scientist Fazlul Sarkar for years, as he (unsuccessfully) sought to expose the identity of a PubPeer commenter who he believes cost him a job offer. In November 2016, the ACLU released a copy of a misconduct investigation report compiled by Wayne State University, which concluded Sarkar ran a laboratory “culture” of “fabrication, falsification and/or plagiarism of data,” and recommended the retraction of 42 papers and correction of 10 papers. He’s now lodged his 19th retraction. Continue reading Caught Our Notice: Researcher who sued PubPeer commenter draws 19th retraction
Elsevier recently retracted the second paper by the duo, a 2015 paper in a cancer journal, after finding evidence of fake peer review. The paper was submitted in October 2014 and accepted just a week before our piece on fake peer review appeared in Nature.
According to the notice, after investigating the paper, which appeared in Cancer Letters, the publisher concluded that it was accepted “based upon the positive advice of at least two faked reviewer reports.” The notice also explained that the identities of several authors “could not be confirmed.” Continue reading Fake peer review strikes again for pair of authors
Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.
One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.
Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Continue reading Breast cancer studies by fired Pfizer employee retracted
Pharmaceutical giant Pfizer has announced it plans to retract five papers by a former employee, after an investigation found duplicated images.
As first reported today by Leonid Schneider, Pfizer has asked to retract five papers from the lab of Min-Jean Yin, a cancer researcher. A spokesperson for the company confirmed to us that Yin had been fired:
…Min-Jean Yin’s employment has been terminated as a result of our investigation.
The five papers to be retracted are: Continue reading Pfizer fires employee, requests five retractions
There’s been a 10th retraction from two former postdocs at a UT-Southwestern cancer research center who were sanctioned by the Office of Research Integrity (ORI) last September, in part due to observations and comments from Retraction Watch readers.
It’s a 2008 Cancer Letters paper, “Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer,” retracted at the request of Makoto Suzuki, the first author who has claimed responsibility for falsifying data in this and five other papers. Continue reading ORI-sanctioned former UT-Southwestern cancer researchers up to 10 retractions
A group at the University of Texas Southwestern led by Adi F. Gazdar that found evidence of inappropriate image manipulation in a number of their papers has retracted its seventh and eighth studies.
Here’s the notice for 2005’s “Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection,” in Oncogene: Continue reading UT-Southwestern cancer researchers up to 8 retractions
Denise Egan, of the Institute of Technology Tallaght in Dublin, and colleagues published “In vitro anti-tumour and cyto-selective effects of coumarin-3-carboxylic acid and three of its hydroxylated derivatives, along with their silver-based complexes, using human epithelial carcinoma cell lines” and “A study of the role of apoptotic cell death and cell cycle events mediating the mechanism of action of 6-hydroxycoumarin-3-carboxylatosilver in human malignant hepatic cells” in 2007.
The two notices say the same thing: Continue reading Two cancer papers retracted because authors “are unable to guarantee the accuracy of some of the figures”
Noriyuki Takai, a gynecologic cancer researcher at Oita University in Japan who retracted three papers last October, has four more retractions, these in Cancer Letters.
All but one of the notices reads as follows: Continue reading Retraction count for gynecologic cancer researcher Takai grows to seven
Whether it’s a one-off or a sign of things to come, Bharat Aggarwal, the MD Anderson scientist at the center of a blogospheric storm—and an institutional investigation—over the validity of his data, has had a paper withdrawn by the journal Cancer Letters. Continue reading MD Anderson researcher Aggarwal loses paper in Cancer Letters